Pharmaceutical fraud encompasses a variety of illegal schemes utilized by pharmaceutical manufacturers, pharmacies, or other health care providers resulting in the submission of claims for reimbursement from government programs for drugs that are improperly manufactured, marketed, or priced.
Kenney & McCafferty has a long history in representing whistleblowers who report securities violations. Since 2010, whistleblowers are able to receive rewards for reporting a wide variety of securities and commodities violations, including late trading, insider trading, money laundering, and violations of the Foreign Corrupt Practices Act. The previously existing SEC whistleblower program only covered insider trading violations.
Oftentimes, whistleblowers who are aware of a False Claims Act violation may not realize that they may be entitled to a reward under the SEC or CTFC Whistleblower Reward Program as well. If a whistleblower has a viable claim under either of these programs in addition to a FCA claim, the two claims would be filed separately, and the filing of one claim would not preclude the filing of the other.